We are planning to recruit eligible participants from participating hospitals. All enrolled patients will have at least one measurable target lesion based on the Response Evaluation Criteria in Solid Tumours, V.1.1.28 (link) Clinical/pathological stage will be based on the tumour node metastasis (TNM) classification established by the International Union Against Cancer.29 (link) For TNM staging, all patients will undergo CT of the thorax and upper abdomen, as well as bone scintigraphy, brain CT, MRI or fluorodeoxyglucose-positron emission tomography. Postoperative local or distant recurrence will be defined as described previously.30 (link) Immunotherapy will be continued until radiographic progression or discontinuation because of severe irAEs or the patient’s request. PD-L1 protein expression will be evaluated using antibody clone 22C3 (Dako, Agilent Technologies, Santa Clara, California, USA). Adverse events will be graded according to Common Terminology Criteria for Adverse Events, V.5.0.
Antibody clone 22c3
Manufactured by Agilent Technologies
Sourced in United States
Antibody clone 22C3 is a laboratory reagent used in the detection and analysis of specific proteins or molecules. It is a highly specific antibody that binds to a target antigen, enabling researchers to identify and quantify the presence of that target. The core function of this antibody is to serve as a tool for targeted protein analysis in various experimental and diagnostic applications.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using antibody clone 22c3
1
Immunotherapy Evaluation for Solid Tumors
2
Immunohistochemical PD-L1 Staining Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
TMA slides were freshly sectioned at five µm and were sent to each of the participating centres. Each centre performed immunohistochemical staining for PD-L1 within 4 weeks, using antibody clone 22C3 (Agilent). Staining was performed using the standard Agilent 22C3 pharmDx Assay or a laboratory developed test (LDT) on Ventana's BenchMark ULTRA (BMU), developed by the University Medical Centre in Groningen, validated against the Agilent 22C3 pharmDx Assay. The pharmDx Assay was available in 7/8 centres and the LDT in 5/8 centres. As a result of the two TMAs and two protocols for immunohistochemical staining, four different subgroups were analysed: TMA-A/22C3 pharmDx, TMA-A/22C3 LDT, TMA-B/22C3 pharmDx and TMA-B/22C3 LDT (online supplementary figure S1).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!